Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Benitec BiopharmaBNTC +3.47%30 3-Year EBITDA Growth Rate is 68.60% as of Mar. 2026, which is 87% above its 10-year median of 36.70. GuruFocus rates BNTC with a GF Score™ of 30/100. Among 1,135 Biotechnology companies, Benitec Biopharma ranks better than 92.78% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 68.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 64.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Benitec Biopharma was 71.70% per year. The lowest was -2.30% per year. And the median was 36.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Benitec Biopharma 3-Year EBITDA Growth Rate Related Terms
BNTC vs EDIT, AUTL, TENX: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Benitec Biopharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benitec Biopharma 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benitec Biopharma's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Benitec Biopharma's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 68.60% mean?
Benitec Biopharma (BNTC) has a 3-Year EBITDA Growth Rate of 68.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Benitec Biopharma and its competitors. This is 87% above median its historical median of 36.70. According to the industry distribution chart, Benitec Biopharma ranks #82 out of 1135 companies in the Biotechnology industry, placing it in the top 7.2%.
Is Benitec Biopharma's 3-Year EBITDA Growth Rate too high?
Benitec Biopharma's current 3-Year EBITDA Growth Rate of 68.60% is 87% above median its 10-year median of 36.70. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Benitec Biopharma's value of 68.60% is 363.5% above this industry median. Based on the distribution chart, Benitec Biopharma ranks #82 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Benitec Biopharma has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's 3-Year EBITDA Growth Rate compare to EDIT and AUTL?
According to the Biotechnology industry distribution chart, Benitec Biopharma ranks #82 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Benitec Biopharma in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.80. Benitec Biopharma's value of 68.60% is 363.5% above this benchmark. While the company's 10-year median is 36.70 vs. the industry median of 14.80, Benitec Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Benitec Biopharma's current 3-Year EBITDA Growth Rate of 68.60% is 363.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Benitec Biopharma and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Benitec Biopharma's current 3-Year EBITDA Growth Rate is 68.60%, which is 87% above median its own 10-year median of 36.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (BNTC) has a current 3-Year EBITDA Growth Rate of 68.60%. The current 3-Year EBITDA Growth Rate is 68.60%, which is 87% above median its 10-year median of 36.70 and 363.5% above the Biotechnology industry median of 14.80. Benitec Biopharma's overall GF Score™ is 30/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current 3-Year EBITDA Growth Rate is 68.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
30GF Score
Get the complete analysis for BNTC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTC has been successfully added to your 
